| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5997903 | WYETH PHARMS | Oral-administration forms of a medicament containing pantoprazol |
Dec, 2016
(7 years ago) | |
|
US5997903 (Pediatric) | WYETH PHARMS | Oral-administration forms of a medicament containing pantoprazol |
Jun, 2017
(6 years ago) | |
| US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(5 months from now) | |
| US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(5 months from now) | |
| US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(5 months from now) | |
|
US7550153 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(11 months from now) | |
|
US7553498 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(11 months from now) | |
|
US7838027 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(11 months from now) | |
| US7544370 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Jun, 2026
(2 years from now) | |
|
US7544370 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Dec, 2026
(2 years from now) | |
Protonix is owned by Wyeth Pharms.
Protonix contains Pantoprazole Sodium.
Protonix has a total of 10 drug patents out of which 2 drug patents have expired.
Expired drug patents of Protonix are:
- US5997903
- US5997903*PED
Protonix was authorised for market use on 12 June, 2001.
Protonix is available in for suspension, delayed release;oral, tablet, delayed release;oral dosage forms.
Protonix can be used as erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd.
The generics of Protonix are possible to be released after 07 December, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-54) | Nov 12, 2012 |
| New Indication(I-614) | Nov 12, 2012 |
| Pediatric Exclusivity(PED) | May 12, 2013 |
Drugs and Companies using
PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date:
12 June, 2001Treatment:
Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerdDosage:
How can I launch a generic of PROTONIX before its drug patent expiration?
More Information on Dosage
PROTONIX family patents
